Lymphoma, Tumors
Conditions
Keywords
Advanced and/or Metastatic Solid Tumors and Lymphoma
Brief summary
This study will research the side effects of pegaspargase (pronounced peg-as-par-gase); its brand name is ONCASPAR® when it is used with another FDA-approved cancer treatment (chemotherapy) drug called gemcitabine HCl (pronounced gem-site-a-bean; its brand name is GEMZAR®.
Detailed description
The purpose of this research study is for the study's sponsor, Enzon Pharmaceuticals, Inc. (Enzon), to learn more about its drug pegaspargase. Pegaspargase is the drug's scientific or generic name. Because it is already approved by the Food and Drug Administration (FDA), it also has a brand name - ONCASPAR®. It is approved by the FDA for the treatment of a type of leukemia (cancer of white blood cells). However, pegaspargase is not approved by the FDA for treatment of the cancer in this study. This study will research the side effects of pegaspargase when it is used with another FDA-approved cancer treatment (chemotherapy) drug called gemcitabine HCl; its brand name is GEMZAR®. It is approved for the treatment of patients with cancer of the pancreas and of patients with breast cancer. However, gemcitabine is not approved by the FDA for treatment of any other types of cancer. In addition, the combination of pegaspargase and gemcitabine for solid tumors and lymphoma in this study is investigational. This type of study treatment is called a combination treatment or a combination study. The information (research data) from this study will be used by Enzon to plan other combination research studies with pegaspargase plus gemcitabine for the treatment of certain cancers.
Interventions
DRUGOncaspar & Gemzar; advanced and/or solid tumors and lymphoma
Sponsors
Enzon Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Capable of understanding the protocol requirements and risks and providing written informed consent. * Histologically or cytologically confirmed diagnosis of advanced and/or metastatic solid tumor or lymphoma (Hodgkin's or non-Hodgkin's), and have either failed primary treatment or there is no available standard treatment. * Prior standard therapy was not effective, or no known therapy will extend survival or provide benefit. * Measurable or evaluable disease. * Age 18 years or older. * Score of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale. * Absolute neutrophil count (ANC)≥ 1500/μL. * Platelet count ≥ 100,000/μL. * Hemoglobin ≥ 9.0 g/dL. * Fibrinogen ≥ 0.75x the lower limit of normal (LLN), and PT, PTT, and INR ≤ 1.5x the upper limit of normal (ULN). * Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min. * Total bilirubin ≤ 1.5 mg/dL. * Transaminases (AST, ALT) ≤ 2.5x the upper limit of normal (ULN) (may be ≤ 5.0x ULN if due to metastatic disease in the liver). * Amylase and lipase levels are within normal limits. Any subject who has given informed consent to participate in the clinical study and who meets all entry criteria for the study may participate in the tumor analysis part of the study.
Exclusion criteria
* Subjects meeting any of the following
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objectives of this Phase 1 study of pegaspargase in combination with gemcitabine are to determine the maximum tolerated dose of IV pegaspargase when administered with gemcitabine | — |
| and to determine the recommended Phase 2 dose of pegaspargase | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objectives of this study are to evaluate the safety and tolerability of the combination study treatment | — |
| to determine the PD/PK profile and immunogenicity of pegaspargase | — |
| to determine the PK profile of gemcitabine when administered in combination with pegaspargase | — |
| and to detect preliminary evidence of tumor | — |
Countries
United States
Outcome results
None listed